GSM: Vaginal and Urinary Symptoms of Menopause

What is GSM?

Genitourinary syndrome of menopause describes genital, sexual and urinary changes associated with declining sex hormones during the menopause transition and afterward. Symptoms can include vaginal or vulvar dryness, burning, irritation, pain with penetration, urinary urgency or recurrent urinary infections. The older term “vaginal atrophy” describes only part of this picture. [1]

The problem is not limited to sex. Clothing, sitting, washing or examinations can become uncomfortable, and urinary symptoms can disrupt ordinary activities. Symptoms are worth discussing even if you do not have hot flashes or do not want systemic HRT. Do not assume that every new symptom is caused by menopause; similar complaints can come from other conditions. [1], [3]

How is the cause assessed?

The AUA guideline bases diagnosis on symptoms, with or without physical findings, after considering other causes and coexisting problems. Tell the clinician where the discomfort occurs, how long it has lasted, whether urination or penetration triggers it, and which products you have tried. Medicines, cancer treatment, irritants and health conditions such as Sjögren’s syndrome can affect dryness. [1], [3]

An examination or targeted testing may help distinguish GSM from infection, vulvar skin disease, pelvic-floor problems or other pathology. Ask what each examination or test would clarify and discuss comfort, consent and any needed adjustments. A hormone concentration alone does not tell the clinician whether a sore area is infected or a skin disorder is present. [1]

Arrange assessment for persistent symptoms, unusual discharge or bleeding after sex, between periods or after menopause. Possible UTI with fever or shivering, flank/back pain, blood in the urine or rapid worsening needs urgent clinical advice. Vaginal estrogen is not an antibiotic or a way to defer assessment of an acute infection. [3], [4]

Which options are worth discussing?

Choice should reflect your most troublesome symptoms, medical history, preferences, cost and ability to use the product. NICE offers vaginal estrogen for menopause-related genitourinary symptoms, including for people already taking systemic HRT. Nonhormonal moisturizers or lubricants can be used alongside it or when estrogen is unsuitable or unwanted. [2]

AUA offers local low-dose estrogen and vaginal DHEA options and conditionally offers ospemifene. NICE places prasterone after ineffective or poorly tolerated vaginal estrogen or nonhormonal options, and considers ospemifene when local application is impractical. These are different guideline approaches, not a universal ladder requiring everyone to fail the same products. [1], [2]

Guideline recommendations can differ from national product labeling. AUA allows vaginal DHEA alongside systemic estrogen as expert opinion, but the UK Intrarosa leaflet does not recommend combining it with systemic HRT, androgen treatment or vaginal estrogen because combination evidence is unavailable. Check the exact product and country with the prescriber; permission to add vaginal estrogen does not automatically extend to every vaginal medicine. [1], [8]

Creams, tablets, inserts and rings have product-specific schedules and applicators. A loading period, maintenance schedule or ring replacement interval cannot be transferred to a different product just because both are called estrogen. See the local estrogen guide and the exact leaflet with your pharmacist. Avoid perfumed washes, douches and ordinary skin creams inside the vagina; use products intended for the area. [2], [3]

How is local treatment different from systemic HRT?

Low-dose local vaginal estrogen is intended mainly for local symptoms. It does not provide the same hot-flash or whole-body replacement treatment as a systemic patch, gel or tablet. Some estrogen enters the bloodstream, but NICE describes this as minimal compared with systemic HRT. Persistent local symptoms can therefore need additional local care even when systemic treatment is helping other symptoms. [2]

Not every vaginal estrogen product is low-dose local treatment. Some vaginal rings deliver systemic estrogen. Confirm the exact product before applying low-dose-local safety or uterine-protection advice. The NAMS 2020 statement says a progestogen is not indicated with low-dose vaginal estrogen, vaginal DHEA or ospemifene, while noting that endometrial safety trials beyond one year were lacking. This is guidance with an evidence limitation, not a declaration of zero lifetime risk or a reason to ignore product-specific warnings. [7], [9]

What does the evidence say, including uncertainty?

The AUA guideline supports several treatments but grades much of the symptom evidence as low certainty. It does not establish that one hormonal option is best for every person. Outcomes, formulations and comparisons vary, and a placebo gel can itself reduce friction. A recommendation is not a promise of a fixed percentage improvement by a particular week. [1]

In a 12-week randomized trial of 302 postmenopausal participants, vaginal estradiol tablets and a moisturizer did not improve the most bothersome symptom significantly more than dual placebo. All groups improved. This does not erase the wider evidence supporting local estrogen, but it shows why response should be assessed and why one product cannot be assumed to solve every cause of discomfort. The trial tested specific products and comparators; it did not prove all options equivalent in every population. [5]

For recurrent urinary infections, AUA recommends low-dose vaginal estrogen to reduce future infections in people with GSM. This is prevention in an appropriate patient, not treatment of the infection happening today. AUA says evidence does not support laser or radiofrequency for GSM symptoms; NICE limits vaginal laser to randomized research. Marketing terms such as “rejuvenation” do not establish benefit. [1], [2]

What changes after breast cancer?

NICE recommends nonhormonal moisturizers or lubricants first for people with a breast-cancer history. If symptoms persist, vaginal estrogen can be considered through a discussion of individual recurrence risk, symptom burden and alternatives. For someone taking an aromatase inhibitor, NICE specifies working with a breast-cancer specialist to identify options. Do not stop cancer treatment or start another hormone on the basis of a general GSM page. [2]

NICE states that whether vaginal estrogen changes recurrence risk is unknown. Low absorption is relevant but does not prove zero risk in every cancer setting. AUA allows low-dose vaginal estrogen after breast cancer in multidisciplinary shared decision-making. These positions support an individualized conversation; they do not mean every local product, DHEA supplement or oral SERM is automatically suitable. [1], [2]

How should response and persistent symptoms be reviewed?

Review whether the symptoms that mattered to you improved, whether the product is usable and whether irritation or new bleeding appeared. NICE recommends review at three months and annually, with earlier review for problems. AUA advises that long-term treatment and follow-up may be needed; symptoms can return when local estrogen is stopped. An arbitrary short course is not the same as a personalized maintenance plan. [1], [2]

Persistent discomfort should prompt a check of the diagnosis, use of the actual product, application difficulties and coexisting problems. Pelvic-floor treatment or another specialist may be relevant for certain pain patterns. Do not keep increasing a cream indefinitely without reviewing what is causing the pain. [1]

AUA advises against endometrial surveillance solely because someone uses low-dose vaginal estrogen, vaginal DHEA or ospemifene. That expert-opinion recommendation concerns routine surveillance; it does not remove the need to investigate unexplained bleeding or other concerning symptoms. [1], [3]

What questions come up in public discussions?

A public August 2026 discussion asks whether persistent local symptoms while using an estrogen patch could justify separate vaginal treatment. It also shows uncertainty about what to ask a clinician. This is a useful question, not evidence that all participants share the same diagnosis or that advice in the comments is safe. We omit usernames, individual regimens and quotations. [6]

A practical way to open the appointment is: “My other symptoms improved, but local discomfort still affects me. Could we check the cause and discuss local options?” You can also ask for help using an applicator, discuss whether a ring or another formulation is practical, and explain if cost or privacy makes consistent treatment difficult. Shared decision-making includes these issues. [1], [2]

What can a symptom note usefully capture?

Choose a few observations: dryness, comfort in everyday activities, pain triggers, urinary symptoms, the actual treatment used and any irritation. Use your own consistent wording rather than trying to infer tissue health from a score. Keep new bleeding separate so it can receive appropriate clinical attention.

A note can say what happened and when without claiming why: “dryness bothered me today; note comfort and questions for review.” A log cannot diagnose infection, establish cancer safety or decide that more estrogen is needed. The genuine app examples below demonstrate symptom selection and a fictional note, not validated medical scoring or a treatment outcome.

Common questions

Can GSM happen while I use an estrogen patch?

Yes. Systemic treatment may not fully relieve local symptoms; NICE allows additional vaginal estrogen where appropriate. [2]

Persistent dryness, discomfort or urinary symptoms are a reason to review the local problem rather than automatically increasing a systemic dose. The cause still needs assessment, and the product selected should fit the symptom and medical history. The local-versus-systemic section explains why the two purposes differ; the diagnosis section describes other causes that may need attention. [1], [2]

Do I need to be sexually active to get care?

No. GSM includes everyday genital discomfort and urinary symptoms, not only pain during sex. [1]

Describe what bothers you in ordinary activities, such as dryness, irritation or discomfort, and mention urinary changes separately. Treatment goals can be comfort and function without any assumption about sexual activity or relationships. You can also explain examination preferences when discussing assessment. The diagnosis section starts with symptoms and context rather than requiring a particular sexual history to make care worthwhile. [1]

Is a moisturizer the same as a lubricant?

No. Moisturizers are used for ongoing dryness support; lubricants reduce friction during activity. [1], [3]

Neither category should be assumed to treat every cause of burning, bleeding or urinary pain. Choose a product intended for the relevant use and discuss persistent irritation or inadequate relief. A response to one preparation also does not establish the diagnosis by itself. The treatment section explains the role of nonhormonal products alongside prescription options and the need to reassess unresolved symptoms. [1], [3]

Does local estrogen treat an active UTI?

No. It may help prevent recurrent infections in suitable patients, but acute symptoms need assessment. [1], [4]

Burning on urination, urgency or other new symptoms can have more than one explanation, so prevention and treatment of a current episode are different decisions. Do not use a routine symptom diary or a maintenance vaginal product as a substitute for care when acute symptoms develop. The assessment section distinguishes infection concerns from ongoing GSM management and includes situations needing prompt attention. [1], [4]

Is every vaginal ring a local low-dose product?

No. Some rings deliver systemic estrogen; confirm the exact product before applying local-treatment advice. [9]

Femring is an example of a vaginal ring with systemic estrogen delivery. It therefore cannot inherit every statement made about a low-dose local product, including assumptions about uterine protection. Ask the pharmacist or prescriber to confirm the brand, delivery and purpose of the ring. The local-versus-systemic section keeps this exception visible instead of classifying all vaginal formulations as equivalent. [9]

Do symptoms always disappear after a short course?

No. Long-term treatment may be needed and symptoms can return after stopping. Review response and maintenance with the clinician. [1], [2]

The appropriate starting and maintenance instructions depend on the named product; recurrence does not justify repeating or increasing a regimen without checking those instructions. Persistent symptoms can also mean the diagnosis, practical use or treatment choice needs another look. Keep track of what improved and what did not. The review section explains why maintenance and reassessment remain part of care. [1], [2]

Does breast-cancer history rule out every local option?

It requires an individualized discussion. Nonhormonal options come first in NICE, with specialist involvement particularly during aromatase-inhibitor treatment. [2]

The decision depends on the current cancer treatment, symptom burden, response to nonhormonal measures and the named product’s labeling. Guidance that allows a shared decision does not prove there is no recurrence risk or erase a label contraindication. Bring the oncology team into the relevant discussion. The breast-cancer section describes the uncertainty and why aromatase inhibitors require particular care. [1], [2]

Is vaginal laser established routine treatment?

No. AUA says evidence does not support it for GSM symptoms; NICE limits it to randomized trials. [1], [2]

A procedure being available commercially is different from having convincing evidence of benefit and safety for this indication. Ask what outcomes were measured, which comparator was used and whether the offer is part of an appropriate research trial. Do not treat promotional before-and-after accounts as equivalent evidence. The evidence section places device claims beside guideline conclusions and established treatment options. [1], [2]

Glossary

Terms that help explain care decisions.

Aromatase inhibitor

Cancer treatment that reduces estrogen production.

DHEA / prasterone

A steroid precursor used in a particular prescription vaginal product.

Dyspareunia

Pain during sexual activity or penetration.

Dysuria

Pain or burning during urination.

Endometrial surveillance

Routine checking of the uterine lining, distinct from investigating symptoms.

Endometrium

The lining inside the uterus.

GSM

Genitourinary syndrome of menopause: genital, sexual and urinary symptoms associated with menopausal hormone changes.

Local low-dose estrogen

Estrogen intended mainly for local genital and related symptoms.

Lubricant

A product used to reduce friction.

Nonhormonal treatment

An approach that does not supply hormones or act as a hormone precursor.

Pelvic floor

Muscles and supporting tissues around the pelvic organs.

Placebo comparison

A trial comparison without the active medicine; a gel can still affect lubrication.

Recurrent UTI

Repeated urinary tract infections requiring a prevention and assessment plan.

SERM

Selective estrogen receptor modulator, such as ospemifene.

Systemic HRT

Hormone treatment that acts through circulation beyond the application site.

Urinary urgency

A sudden compelling need to urinate.

Vagina

The internal muscular canal between the vulva and cervix.

Vaginal moisturizer

A product intended for ongoing vaginal moisture support.

Vulva

External genital tissues, distinct from the vaginal canal.

Vulvovaginal atrophy

An older description of tissue changes that covers only part of GSM.

How was this guide researched?

Sources and limits

This AI-assisted guide uses original guidance, public health sources and the studies listed below. It separates recommendations, direct findings and unresolved questions. Public experiences identify concerns without measuring their frequency. No independent clinician review is claimed. Doserly develops a commercial tracking app. Figures are original explanatory syntheses; genuine app captures contain fictional examples.

Medical claims were checked October 2, 2026. Differences between populations and guidelines are retained. Appointment-preparation advice is editorial, not a validated diagnostic tool. New guidance or material safety information triggers review. Report a correction to Doserly support with its source.

Sources